financetom
Business
financetom
/
Business
/
Santos extends exclusivity for $18.7 billion ADNOC-led offer, profit declines
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Santos extends exclusivity for $18.7 billion ADNOC-led offer, profit declines
Aug 24, 2025 6:06 PM

*

Exclusivity period extended to September 19

*

HY profit falls 22.3% but beats analysts' estimates

*

Interim dividend 13.4 cents per share

(Adds details, background in throughout)

Aug 25 (Reuters) - Australian gas producer Santos

on Monday agreed to further extend the exclusivity

period for an $18.7 billion takeover bid from a group led by Abu

Dhabi National Oil Co (ADNOC), and reported a better-than-feared

22% drop in first-half profit.

Its shares rose 1% in early trading after extending the due

diligence period to September 19 to give the consortium led by

ADNOC's investment arm XRG more time to secure required internal

approvals before making a binding takeover offer.

Santos said the consortium had on Sunday "again confirmed it

has not found anything in due diligence that would lead it to

withdraw its indicative proposal".

Analysts said the shares would likely be supported on Monday

by confirmation the deal was still progressing despite the

delays.

The company reported its first-half underlying earnings fell

to $508 million from $654 million a year earlier, hurt by weaker

realised prices for its liquefied natural gas (LNG) and oil. The

result was 3% above Visible Alpha forecast consensus.

While Santos shares rose to A$7.81 per share in early

trading after the two announcements, they remain more than a

dollar below the consortium's proposed offer of A$8.89 apiece.

The gain outpaced a 0.75% rise in the broader S&P/ASX200

index.

Santos last week flagged the consortium, which includes Abu

Dhabi Development Holding Company (ADQ) and private equity firm

Carlyle, would face a delay in finalising the offer for at least

a month.

The deadline for the exclusive talks between Santos and the

consortium expired last Friday. Santos can engage with a bidder

if a higher offer is made, but is prevented from talks with any

parties who match the XRG offer.

The proposed offer requires approval from regulators in

Australia, Papua New Guinea, and the U.S. given Santos holds

assets in each of those jurisdictions.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Analysis-Britain appeals to Big Tech with change of regulatory guard
Analysis-Britain appeals to Big Tech with change of regulatory guard
Jan 23, 2025
LONDON (Reuters) - Britain's choice of a former Amazon executive to chair its antitrust regulator is a clear pitch for investment, including from Big Tech, and signals it is prepared to go easier on deal-making if that would help, company bosses and lawyers said. Doug Gurr, former boss of the U.S. online retailer's UK operation, was picked to chair the...
BRIEF-Morgan Stanley CEO Ted Pick Says I Am Bullish On The M&A Cycle - CNBC Interview
BRIEF-Morgan Stanley CEO Ted Pick Says I Am Bullish On The M&A Cycle - CNBC Interview
Jan 23, 2025
Jan 23 (Reuters) - * MORGAN STANLEY ( MS ) CEO TED PICK SAYS I AM BULLISH ON THE M&A CYCLE -CNBC INTERVIEW Source text: Further company coverage: ...
Troilus Gold Makes Leadership Appointments as Project Development Advances
Troilus Gold Makes Leadership Appointments as Project Development Advances
Jan 23, 2025
07:59 AM EST, 01/23/2025 (MT Newswires) -- Troilus Gold ( CHXMF ) said Thursday that it expanded its engineering team with three appointments as it continues to advance the Troilus project in Quebec. The company appointed Denis Rivard as executive vice president of projects and named Chris Sharpe vice president of technical services, effective Feb. 1. Troilus Gold ( CHXMF...
Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment
Biogen Gets FDA, EMA Approval to Study Higher Dose Regimen of Spinal Muscular Atrophy Treatment
Jan 23, 2025
07:55 AM EST, 01/23/2025 (MT Newswires) -- Biogen (BIIB) announced Thursday that the US Food and Drug Administration has accepted its supplemental new drug application and that the European Medicines Agency has validated the application for a higher dose regimen of its experimental drug, nusinersen, for spinal muscular atrophy. The company said it would study the efficacy of a higher...
Copyright 2023-2026 - www.financetom.com All Rights Reserved